Cat. No. 1937
Chemical Name: 1H-Pyrazolo[3,4-b]quinoxalin-3-amine
Biological ActivityInhibitor of cyclin-dependent kinases (cdks) and glycogen synthase kinase-3 (GSK-3). IC50 values are 0.6, 0.4 and 1 μM for cdk1/cyclin B, cdk5/p25 and GSK-3 respectively.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Monge et al (1995) 3-Amino-2-quinoxalinecarbonitrile. New fused quinoxalines with potential cytotoxic activity. J.Heterocycl.Chem. 31 1135.
Ortega et al (2002) Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorg.Med.Chem.Lett. 10 2177. PMID: 11983514.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: NSC 693868, supplier, GSK-3, inhibitors, cdks, GSK, Glycogen, Synthase, Kinases, 3, Cyclin-Dependent, Protein, Carbohydrate, Metabolism, NSC693868
Find multiple products by catalog number
New Products in this Area
Cyclin-dependent kinase inhibitorGSK2578215A
Potent, selective LRRK2 inhibitor; brain penetrantAmlexanox
Inhibitor of TBK1 and IKKε; antiallergic agentPF 05212384
Potent and selective dual PI 3-kinase/mTOR inhibitorPF 03814735
Aurora kinase A and B inhibitorPF 04691502
Dual PI 3-K/mTOR inhibitorTNP
Inhibitor of IP6K; also inhibits IP3KACHP
Selective IKKα and IKKβ inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantCZC 24832
Selective inhibitor of PI 3-Kinase γLY 333531 hydrochloride
Protein kinase C inhibitor; selective for β isozymesPF 06465469
Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK10Z-Hymenialdisine
Pan kinase inhibitor; potently inhibits MEK-1CP 690550 citrate
Potent JAK inhibitorWYE 687 dihydrochloride
Potent and selective mTOR inhibitorN,N-Dimethylsphingosine
Sphingosine kinase inhibitorPEP 005
Protein kinase C activatorCZC 54252 hydrochloride
Potent LRRK2 inhibitor; neuroprotectiveBisindolylmaleimide II
Potent PKC inhibitor and nicotinic receptor antagonistCID 2011756
Pan protein kinase D (PKD) inhibitor; cell permeable
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.